Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the development and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist.
Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSEhcp.com to see the full Prescribing Information and learn more.
Pittsburgh Territory Business Manager
716-474-5987 cell phone
Check out “Tava Itp-20213-Tavalisse Clinical Data Compendium Kol Video” from Rigel Pharmaceuticals, Inc. on Vimeo.
The video is available for your viewing pleasure at https://vimeo.com/572810213